Research programme: inflammatory disease therapeutics - Vivtex Corporation/AI Proteins
Latest Information Update: 01 Mar 2024
At a glance
- Originator AI Proteins; Vivtex Corporation
- Class Anti-inflammatories
- Mechanism of Action Tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation